BACKGROUND/AIMS: To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006. METHODS: Three hundred and eighty HIV-HCV co-infected patients were prospectively included in surveys from November 22 to 29, 2004 (2004 survey), and 416 from April 3 to 10, 2006 (2006 survey). RESULTS: Patients in 2006 compared to those in 2004 had negative HCV RNA more often (24% vs. 12%). The rate of liver biopsy was similar (56% vs. 54%) while 24% had had a non-invasive liver damage assessment. The rate of previous treatment for HCV infection was higher (48% vs. 26%). The main reasons for HCV non-treatment have changed: HCV treatment deemed questionable (44% vs. 53%), lack of liver biopsy (18% vs. 33%), physicians' conviction of poor patient compliance (20% vs. 30%). In both surveys, HCV treated patients were more often of European origin, had better control of HIV infection, and had a liver damage assessment more often. CONCLUSIONS: The care of HIV-HCV co-infected patients has changed significantly in "real life". These results underline the importance of continuing efforts to educate physicians and patients in order to increase the access of co-infected patients to HCV treatment.
BACKGROUND/AIMS: To analyze the barriers to HCV treatment in HIV-HCV co-infectedpatients and their evolution between 2004 and 2006. METHODS: Three hundred and eighty HIV-HCV co-infectedpatients were prospectively included in surveys from November 22 to 29, 2004 (2004 survey), and 416 from April 3 to 10, 2006 (2006 survey). RESULTS:Patients in 2006 compared to those in 2004 had negative HCV RNA more often (24% vs. 12%). The rate of liver biopsy was similar (56% vs. 54%) while 24% had had a non-invasive liver damage assessment. The rate of previous treatment for HCV infection was higher (48% vs. 26%). The main reasons for HCV non-treatment have changed: HCV treatment deemed questionable (44% vs. 53%), lack of liver biopsy (18% vs. 33%), physicians' conviction of poor patient compliance (20% vs. 30%). In both surveys, HCV treated patients were more often of European origin, had better control of HIV infection, and had a liver damage assessment more often. CONCLUSIONS: The care of HIV-HCV co-infectedpatients has changed significantly in "real life". These results underline the importance of continuing efforts to educate physicians and patients in order to increase the access of co-infected patients to HCV treatment.
Authors: Marc-Arthur Loko; Dominique Salmon; Patrizia Carrieri; Maria Winnock; Marion Mora; Laurence Merchadou; Stéphanie Gillet; Elodie Pambrun; Jean Delaune; Marc-Antoine Valantin; Isabelle Poizot-Martin; Didier Neau; Philippe Bonnard; Eric Rosenthal; Karl Barange; Philippe Morlat; Karine Lacombe; Anne Gervais; François Rouges; Alain Bicart See; Caroline Lascoux-Combe; Daniel Vittecoq; Cécile Goujard; Claudine Duvivier; Bruno Spire; Jacques Izopet; Philippe Sogni; Lawrence Serfaty; Yves Benhamou; Firouzé Bani-Sadr; François Dabis Journal: BMC Infect Dis Date: 2010-10-22 Impact factor: 3.090
Authors: Adeel A Butt; Uzma A Khan; Obaid S Shaikh; Deborah McMahon; Zachariah Dorey-Stein; Joel Tsevat; Vincent Lo Re Journal: HIV Clin Trials Date: 2009 Jan-Feb
Authors: Dominique Salmon-Ceron; Julien Cohen; Maria Winnock; Perrine Roux; Firouze Bani Sadr; Eric Rosenthal; Isabelle Poizot Martin; Marc-Arthur Loko; Marion Mora; Philippe Sogni; Bruno Spire; François Dabis; Maria Patrizia Carrieri Journal: BMC Health Serv Res Date: 2012-03-12 Impact factor: 2.655